サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：電子臨床成果評価ソリューションの世界市場：2023-2030
市場調査レポート
商品コード
1279675

電子臨床成果評価ソリューションの世界市場：2023-2030

Global Electronic Clinical Outcome Assessment Solutions Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 194 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
電子臨床成果評価ソリューションの世界市場：2023-2030
出版日: 2023年05月26日
発行: DataM Intelligence
ページ情報: 英文 194 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

電子臨床成果評価ソリューションの世界市場は、2022年に12億3,900万米ドルに達し、2030年には42億4,980万米ドルに達することで有利な成長が予測されます。また、予測期間中（2023年～2030年）のCAGRは17.3%に達すると予測されています。

電子臨床成果評価ソリューションは、医師が無作為化臨床研究を迅速かつ効果的に実施するためのツールです。これらのeCOAシステムは、多数の場所から一貫してデータを収集し、患者の安全性と採用プロセスを向上させるのに役立ちます。初期段階の試験がより優先されるようになったため、エンドユーザーはこれらのシステムをより頻繁に利用するようになりました。

電子臨床成果評価ソリューション市場には、ライセンス方式、クラウドベース方式、ウェブホスティング方式の提供方法があり、これらの製品の市場シェアを高めています。患者報告評価、臨床医報告評価、観察者報告評価、パフォーマンス評価などのアプローチは、電子臨床成果評価ソリューションの範囲に含まれるため、市場シェアが拡大しているのです。

市場力学

大手製薬会社やバイオ医薬品会社による臨床試験研究の外部化の進展が、電子臨床成果評価ソリューション市場の成長を牽引しています。

慢性疾患の有病率の増加、新しい治療法の開発、新製品の発売、電子プラットフォームなどの技術向上などが、世界の電子臨床成果評価ソリューション市場の成長に寄与しています。

治療効果をより正確に把握するために、規制当局は患者の幸福度をより幅広く調査することの重要性を強調しています。そのため、さまざまな慢性疾患に対する治療の有効性を評価するために、臨床転帰評価（COA）が頻繁に使用されるようになってきています。また、新薬の承認に貢献するケースもあります。

また、数多くの新サービスがイントロダクションとして導入されることで、市場は拡大します。例えば、2021年6月、シグナントヘルス社は、提供される臨床データの品質を損なうことなく、試験の設定時間を50％以上短縮する新しい加速プログラムを発表し、市場の大幅な拡大につながっています。

研究開発費の増大と技術の進歩がメーカーに有利な機会を生み出す

電子臨床成果評価ソリューションは、多くの臨床試験でより広く受け入れられるようになってきているため、大きな市場機会があります。電子臨床成果評価ソリューションに利用されるアプローチや製品への需要が高いため、メーカーは成長のための有益な選択肢を得ることができると思われます。

主要企業が最先端の技術改良のために研究開発能力に多額の投資をしているため、新興国市場にはチャンスがあるのです。数多くの企業が、複数の疾患を治療するための最先端技術を開発し、臨床試験を通じて最適な治療法を評価しています。

導入コストの高さが市場成長の妨げになります

中堅の製薬会社や臨床試験スポンサーの間では、eCOAソリューションの構築にかかる初期費用の高さへの懸念が高まっています。電子データ収集には、多額の初期費用（例えば、ソフトウェア付きタブレットやコンピュータの購入、設備費用、ソフトウェア開発者との契約、携帯電話のインターネット利用など）が必要な場合があります。

COVID-19影響分析

COVID-19の分析には、Pre-COVIDシナリオ、COVIDシナリオ、Post-COVIDシナリオに加え、価格力学（パンデミック時の価格変動、COVIDシナリオとの比較）、需給スペクトル（取引制限、ロックダウン、その後の問題による需要と供給のシフト）、政府の取り組み（政府機関による市場、産業、部門の活性化の取り組み）、メーカーの戦略的取り組みが含まれています。

ロシア・ウクライナ紛争影響分析

ロシア・ウクライナ紛争は、この地域の主要な市場プレイヤーの数が少ないため、世界の電子臨床成果評価ソリューション市場に与える影響は少ないと推定されます。しかし、原材料の輸出入の影響は、予測期間中、世界の電子臨床成果評価ソリューション市場の成長にほとんど影響を与えないと予想されます。

目次

第1章 調査手法とスコープ

  • 調査手法
  • 調査目的および調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

  • 配信モード別スニペット
  • アプローチ別スニペット
  • エンドユーザー別スニペット
  • 地域別スニペット

第4章 市場力学

  • 影響要因
    • 促進要因
      • 大手製薬会社やバイオ医薬品会社別臨床試験研究の外部化の増加
      • クラウドベースのサービスに対する需要の高まり
    • 抑制要因
      • 導入コストの高さ
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 法規制の分析

第6章 COVID-19の分析

  • COVID-19の分析
    • COVID-19登場前シナリオ
    • 現在のCOVID-19シナリオ
    • COVID-19後または将来のシナリオ
  • COVID-19の中での価格・ダイナミクス
  • 需給スペクトル
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的な取り組み
  • サマリー

第7章 デリバリーモード別

  • ウェブホスト型
  • クラウドベース
  • ライセンシングインダストリー

第8章 アプローチ別

  • 患者報告型評価
  • 臨床医報告型評価
  • オブザーバー報告型評価
  • パフォーマンス・評価

第9章 エンドユーザー別

  • 製薬会社・バイオ医薬品会社
  • 外来診療センター
  • 研究開発受託機関
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • その他アジア太平洋地域
  • 中東・アフリカ地域
    • 地域別の主なダイナミクス

第11章 競合情勢

  • 競合シナリオ
  • 市況ポジショニング/シェア分析
  • M&A（合併・買収）分析

第12章 企業プロファイル

  • IQVIA Holdings Inc
    • 企業概要
    • デリバリーモードのポートフォリオと説明
    • 財務概要
    • 主な発展状況
  • Oracle Corporation
  • Dassault Systems SE
  • Parexel International Corporation
  • IBM Corporation
  • Signant Health
  • Clario
  • eClinical Solutions LLC
  • Castor
  • Anju Software

第13章 付録

目次
Product Code: HCIT4784

Market Overview

The global electronic clinical outcome assessment solutions market reached US$ 1,239.0 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 4,249.8 million by 2030. The market is expected to exhibit a CAGR of 17.3% during the forecast period (2023-2030).

Clinical Outcome Assessment (eCOA) Solutions are tools that let doctors conduct randomized clinical studies quickly and effectively. These eCOA systems help collect data consistently from numerous locations to improve the safety of patients and the hiring process. End users utilize these systems more often because early-phase testing is being prioritized more.

The electronic clinical outcome assessment solutions market includes licensed, cloud-based, and web-hosted delivery methods, which has increased the market share for these products. The approaches such as patient-reported outcome, clinician-reported outcome, observer-reported outcome, and performance outcome fall under the purview of electronic clinical outcome assessment solutions, which has increased its market share.

Market Dynamics

Increasing Externalization of Clinical Trial Studies by Large Pharmaceutical And Biopharmaceutical Companies Drives the Growth of the Electronic Clinical Outcome Assessment Solutions Market.

The prevalence of chronic illnesses is increasing, new treatment methods are being developed, new products are being released, and technology improvements such as electronic platforms are all contributing to the growth of the global electronic clinical outcome assessment solutions market.

In order to more accurately characterize therapeutic gain, regulatory agencies have stressed the significance of examining broader elements of patient well-being. Clinical outcome assessments (COAs) are therefore being used more frequently to evaluate the effectiveness of treatments for different chronic conditions. In certain instances, they have even contributed to the approval of new drugs.

The market will also expand as a result of the introduction of numerous new services. For instance, in June 2021, Signant Health unveiled a new acceleration program that reduces study setup time by 50 percent or more without compromising the caliber of clinical data delivered, leading to significant market expansion.

Growing R&D Expenditure and Technological Advancements Creates Lucrative Opportunities for Manufacturers.

There is a sizable market opportunity for electronic clinical outcome assessment solutions as it is becoming more widely acceptable in numerous clinical trials. Manufacturers are going to have profitable choices for growth as demand for approaches and products utilized for electronic clinical outcome assessment solutions will be high.

Due to key players' significant investments in research and development capabilities for cutting-edge technical improvements, there is a developing market opportunity. Numerous businesses are creating cutting-edge technologies to treat several conditions, and evaluate the best treatment options via clinical trials.

The High Cost of Implementation Will Hamper the Market Growth.

Concern over the initial high cost of creating an eCOA solution is growing among mid-sized pharmaceutical producers and clinical trial sponsors. Electronic data collection may need a substantial initial financial outlay (for instance, to purchase tablets or computers with software, incur equipment costs, engage software developers, or use cellular internet).

COVID-19 Impact Analysis

The COVID-19 analysis includes the Pre-COVID Scenario, COVID Scenario, and Post-COVID Scenario in addition to pricing dynamics (including pricing change during and after the pandemic evaluating it with pre-COVID scenarios), demand-supply spectrum (shift in demand and supply due to trading restrictions, lockdown, and afterward issues), government initiatives (initiatives to reactivate a market, industry, or sector by government bodies), and manufacturers strategic initiatives.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a low impact on the global electronic clinical outcome assessment solutions market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global electronic clinical outcome assessment solutions market growth over the forecast period.

Segment Analysis

The global electronic clinical outcome assessment solutions market is segmented based on delivery mode, approach, end-user, and region.

Patient Reported Outcome From Approach Segment Accounts for 46.7% of Electronic Clinical Outcome Assessment Solutions Market Share Owing to Rising Technological Advancements.

The health state of a patient is evaluated using patient-reported outcome measures (PROMs) at a certain period. The PROMs tools can be used to treat a problem while it is being treated or while the patient is unwell. The effectiveness of an intervention can occasionally be assessed using pre- and post-event PROMs.

In order to receive high-quality clinical care, patients must be able to describe their symptoms, feelings, and any side effects from any prescribed medications. The pharmaceutical business understood how critical it was to take patient-reported outcomes (PROs) and biomarkers of health improvement into account.

When medical service research started emphasizing enhancing patients' quality of life while undergoing optimal medical therapy, the distinction between medical results and treatment outcomes became more distinct. Consequently, the demand for identifiable, reliable, and valid patient-reported measures (PROMs) increased.

Geographical Analysis

North America Accounted for Approximately 33.9% of the Market Share Owing to the Strong Presence of Major Players and Increasing Research and Development.

Manufacturers have chances to expand their operations in this region because of the rising demand for electronic clinical outcome assessment solutions for various disorders in North America. This region has many producers and suppliers, and its rapid economic development has raised industrial production of electronic clinical outcome assessment solutions products, which has increased the demand.

The marketplace for electronic clinical outcome assessment solutions is anticipated to grow quickly as a result of an increase in clinical trials across the continent. As demand for medicinal research increases, clinical trials are expanding more and more in the US and Canada. Clinicians around the area rely on cutting-edge technologies for data management. Clinicians advise using eCOA options for clinical trial planning because to the necessity of their accessibility.

Competitive Landscape

The major global players in the electronic clinical outcome assessment solutions market include: IQVIA Holdings Inc, Dassault Systems SE, Oracle Corporation, Parexel International Corporation, Signant Health, IBM Corporation, Clario, Castor, eClinical Solutions LLC and Anju Software among others.

Why Purchase the Report?

  • To visualize the global electronic clinical outcome assessment solutions market segmentation based on delivery mode, approach, end-user and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of electronic clinical outcome assessment solutions market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global electronic clinical outcome assessment solutions market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Delivery Mode
  • 3.2. Snippet by Approach
  • 3.3. Snippet by End-User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing externalization of clinical trial studies by large pharmaceutical and biopharmaceutical companies
      • 4.1.1.2. Growing demand for cloud based services
    • 4.1.2. Restraints
      • 4.1.2.1. High cost of implementation
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Before COVID-19 Scenario
    • 6.1.2. Present COVID-19 Scenario
    • 6.1.3. Post COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Delivery Mode

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Delivery Mode
    • 7.1.2. Market Attractiveness Index, By Delivery Mode
  • 7.2. Web Hosted *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Cloud-Based
  • 7.4. Licensed Industries

8. By Approach

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 8.1.2. Market Attractiveness Index, By Product
  • 8.2. Patient-reported outcome *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Clinician-reported outcome
  • 8.4. Observer-reported outcome
  • 8.5. Performance outcome

9. By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Pharmaceutical & Biopharmaceutical Companies *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Ambulatory Care Center
  • 9.4. Contract Research Organizations
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Delivery Mode
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Approach
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Delivery Mode
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Approach
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Delivery Mode
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Approach
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Delivery Mode
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Approach
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan

Australia

      • 10.5.6.4. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Delivery Mode
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Approach
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. IQVIA Holdings Inc *
    • 12.1.1. Company Overview
    • 12.1.2. Delivery Mode Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Oracle Corporation
  • 12.3. Dassault Systems SE
  • 12.4. Parexel International Corporation
  • 12.5. IBM Corporation
  • 12.6. Signant Health
  • 12.7. Clario
  • 12.8. eClinical Solutions LLC
  • 12.9. Castor
  • 12.10. Anju Software

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us